Industry News

Cardiorentis, Roche collaborate on Ularitide

Centerwatch - Fri, 2014-10-17 08:49
Cardiorentis, a Switzerland-based, privately held biopharmaceutical company, is collaborating with Roche to establish the therapeutic efficacy and safety of Ularitide, the company's investigational drug for acute heart failure (AHF). Cardiorentis will incorporate Roche's advanced in vitro diagnostic tests into its TRUE-AHF phase III study to characterize the pharmacological properties of Ularitide, evaluate its benefit-risk profile and the appropriate clinical application in patients.
Categories: Industry News

Sanofi Pasteur, Immune Design collaborate on herpes simplex virus therapy

Centerwatch - Fri, 2014-10-17 08:48
Immune Design, a California-based clinical-stage immunotherapy company, has entered into a broad collaboration for the development of a herpes simplex virus (HSV) immune therapy with Sanofi Pasteur, the vaccines division of Sanofi.
Categories: Industry News

AstraZeneca, University of Cambridge strengthen partnership

Centerwatch - Fri, 2014-10-17 08:46
AstraZeneca, together with its global biologics R&D arm MedImmune, has entered into four new collaborations with the University of Cambridge, building further on their existing partnership. The latest collaborations reinforce AZ’s commitment to creating a permeable research infrastructure in Cambridge following its decision to locate one of its three global R&D centers and its global headquarters in the city, which has been home to MedImmune’s biologics research laboratories for 25 years.
Categories: Industry News

Aduro, Johnson & Johnson Innovation and Janssen expand collaboration

Centerwatch - Fri, 2014-10-17 08:44
Aduro BioTech, a Berkeley, Calif.-based, private, clinical-stage biotechnology company focused on immunotherapy for cancer, has entered into its second agreement with Janssen Biotech, part of Johnson & Johnson, granting an exclusive, worldwide license to certain product candidates engineered for the treatment of lung cancer and certain other cancers based on its novel LADD immunotherapy platform.
Categories: Industry News

Bone Biologics completes merger with AFH Acquisition X

Centerwatch - Fri, 2014-10-17 08:34
Bone Biologics, a California-based company developing a proprietary protein for use in bone regenerative medicine using the patented recombinant human protein known as UCB-1 (or Nell-1) for use with patients undergoing spinal fusion, has completed a reverse merger with AFH Acquisition X, a fully-reporting company with the Securities and Exchange Commission. The combined company changed its name to Bone Biologics.
Categories: Industry News

BBK acquires MEDL Mobile, company instrumental in developing its leading mobile app

Centerwatch - Thu, 2014-10-16 10:37
BBK Holdings announced this morning it will acquire the custom application development division of MEDL Holdings, a developer of mobile applications that has been a long-time partner and collaborator in BBK’s mobile application for patient and site engagement, My Clinical Study Buddy.
Categories: Industry News

Treeway, LACDR collaborate on ALS therapy development

Centerwatch - Thu, 2014-10-16 10:36
Treeway, a Netherlands-based, amyotrophic lateral sclerosis (ALS) R&D strategy-focused company, and the Leiden Academic Center for Drug Research (LACDR) at the University of Leiden, the Netherlands, have formed a collaboration focused on the optimization of clinical trial designs and data analysis for ALS through the use of population disease progression models. Both parties aim to obtain a better understanding of the disease by developing ALS physiology-based disease models and test the effect of interventions in the different identified pathways.
Categories: Industry News

Servier Canada opens Clinical Development Center in Montreal

Centerwatch - Thu, 2014-10-16 10:34
Servier Canada, the Canadian subsidiary of Servier, has opened its new Clinical Development Center in Montreal.
Categories: Industry News

Report: metastatic breast cancer research underfunded

Centerwatch - Thu, 2014-10-16 10:32
While metastatic breast cancer (MBC) claims the lives of 40,000 women and men in America every year and 20-30% of those diagnosed with early stage breast cancer will go on to develop recurrent, metastatic disease, awareness remains low and only 7.1% of breast cancer research investments over the last dozen years were focused on MBC, according to MBC Alliance’s report Changing the Landscape for People Living with Metastatic Breast Cancer.
Categories: Industry News

Moderna, Karolinska Institute to collaborate on messenger RNA therapeutics

Centerwatch - Thu, 2014-10-16 10:30
Moderna Therapeutics, a Cambridge, Mass.-based pharma, has formed a strategic, long-term collaboration with Karolinska Institute (KI) and Karolinska University Hospital (KUH), both in Sweden, for the discovery and development of innovative drugs using Moderna's messenger RNA (mRNA) Therapeutics technology. mRNA Therapeutics enable the in vivo production of both intracellular proteins and secreted proteins.
Categories: Industry News

NIH awards $15.6 million for pulmonary research program

Centerwatch - Thu, 2014-10-16 10:29
The NIH has awarded up to $15.6 million in grants over five years to the University of North Carolina, Chapel Hill (UNC-CH) and the University of Colorado, Denver (UCD) to conduct research with mucolytic agents discovered by Parion Sciences, a Durham, N.C.-based company focused on pulmonary and ocular diseases, and to enable Investigational New Drug applications for Parion's molecules.
Categories: Industry News

New U.K. health campaign urges people with diabetes to 'TALK Hypos'

Centerwatch - Thu, 2014-10-16 10:27
The TALK Hypos awareness campaign has launched in the U.K., supported by Novo Nordisk and Diabetes U.K., encouraging people with diabetes to report hypoglycemia (hypos) to their doctor or nurse.
Categories: Industry News

West Pharmaceutical Services, HealthPrize Technologies to reward patient adherence

Centerwatch - Thu, 2014-10-16 10:26
West Pharmaceutical Services and HealthPrize Technologies are teaming up to reward patients for taking their medications.
Categories: Industry News

Inversion rule change prompts AbbVie to halt Shire takeover

Centerwatch - Thu, 2014-10-16 10:21
In what could have been a major pharmaceutical acquisition and one of the biggest tax inversion deals, Chicago-based AbbVie has recommended its shareholders vote against its proposed $54 billion takeover of Shire, a Dublin-headquartered pharmaceutical company specializing in medications to treat attention deficit disorder and rare diseases
Categories: Industry News

Pediatric Exclusivity Statistics

FDA News - Thu, 2014-10-16 09:28
Updated list.
Categories: Industry News

Spectrum of Diseases/Conditions

FDA News - Thu, 2014-10-16 09:20
Updated list.
Categories: Industry News

Synthetic Biologics fills irritable bowel syndrome Clinical Advisory Board

Centerwatch - Thu, 2014-10-16 08:29
Synthetic Biologics, a biotechnology company developing novel anti-infective biologics and drugs targeting specific pathogens that cause serious infections and diseases, has expanded its Clinical Advisory Board (CAB) created to support development of SYN-010, the company's statin-class candidate intended to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS).
Categories: Industry News

CytRx appoints Steven A. Kriegsman as chairman of the board

Centerwatch - Thu, 2014-10-16 08:21
CytRx, a biopharmaceutical R&D company specializing in oncology, has appointed Steven A. Kriegsman, president, CEO and a director of the company, as chairman of the board, effective Oct. 15. He replaces Max E. Link, Ph.D., whose unexpected passing was announced on Oct. 7.
Categories: Industry News

Genspera hires Melanie Thomas as medical advisor

Centerwatch - Thu, 2014-10-16 08:08
GenSpera, a developer of prodrug therapeutics for the treatment of cancer, has hired Melanie Thomas, M.D., MS, as medical advisor.
Categories: Industry News

Immatics, BioNTech advance personalized cancer vaccines into clinical trials

Centerwatch - Thu, 2014-10-16 08:00
BioNTech and immatics biotechnologies are moving a novel concept of fully personalized therapeutic cancer vaccines, Glioma Actively Personalized VAccine Consortium (GAPVAC), into the clinic. The German national authority, the Paul-Ehrlich-Institute (PEI), has approved the start of a phase I/II study, GAPVAC-101, which applies for the first time the concept of treating glioblastoma patients based on drugs designed and manufactured for each patient individually according to specific characteristics of their tumor and immune system.
Categories: Industry News
Syndicate content